The Ministry of Health, Labor and Welfare granted Kyorin Pharmaceutical Co., Ltd. a license. marketing “Zymso 50% Intravenous Solution” for interstitial cystitis in Japan. Kyorin Pharmaceutical Company Limited is a wholly owned subsidiary of KYORIN Holdings, Inc.
Kyorin Pharmaceutical Company Limited a wholly owned subsidiary of KYORIN Holdings, Inc., has launched the interstitial cystitis product "Zymso® Intravesical Solution 50%"
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5257
Published Date: Sep 25, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing prevalence of interstitial cystitis and growing innovation and product launches are some of the major factors anticipated to drive the growth of the interstitial cystitis drug market.
The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024 â€“ 2036.
The major players in the market are of Johnson & Johnson, Kyorin Pharmaceutical Co Ltd., UCB Pharma, Bayer AG, Eli Lilly and Company, Lipella Pharmaceuticals and others.
The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.